Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents.
about
Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experienceEarly mortality and overall survival in oncology phase I trial participants: can we improve patient selection?Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin.Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience.Phase I trial outcomes in older patients with advanced solid tumoursCreatinine clearance is associated with toxicity from molecularly targeted agents in phase I trialsAn inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials.Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis.Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience.Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation.Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trials.Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials.Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience.Phase I trials involving radiation therapy, quantifying the risks.
P2860
Q33399986-CF3241D4-8296-4032-B628-7E32F02993D3Q34040965-0EA0F77A-88D4-49AA-8414-3E03509D6041Q35584482-4D92294C-57B7-4B96-A6C3-5C929FDF52B0Q36288003-A840DBAA-C50F-4E09-9EC0-B878A19A6DB6Q36510136-F6946A7C-1877-48E1-A467-7ECD58257072Q36547934-33B6656C-C55F-4505-8CBC-720847D4148EQ37364612-C5CFF006-A6E6-4ACF-B1C9-89E4C246C776Q37444815-30056B77-5997-4A88-ADAC-089ED09E3CA4Q37744341-DC01E654-F937-466F-B3F2-0B90FD90C3E4Q43455943-9A5F0932-2EF4-4181-AAE9-E12327FED482Q43536539-CB1B0E43-CD52-43D7-B6F9-50ADD60A8719Q44616007-86AD88C9-4596-42D3-8F87-15C7BD43DD1AQ44932310-FC00806E-D6D7-4CC2-9833-8D4FD0CE6363Q47222469-518E2694-44AF-4DB5-B322-033A24A4D541Q53577839-14C000CE-B543-41E4-91D2-BD2DD51BB420Q54526137-D2263517-6971-46D7-A43B-5F4657B5A630
P2860
Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Comparison of prognostic facto ...... gs vs new noncytotoxic agents.
@ast
Comparison of prognostic facto ...... gs vs new noncytotoxic agents.
@en
type
label
Comparison of prognostic facto ...... gs vs new noncytotoxic agents.
@ast
Comparison of prognostic facto ...... gs vs new noncytotoxic agents.
@en
prefLabel
Comparison of prognostic facto ...... gs vs new noncytotoxic agents.
@ast
Comparison of prognostic facto ...... gs vs new noncytotoxic agents.
@en
P2093
P2860
P356
P1476
Comparison of prognostic facto ...... ugs vs new noncytotoxic agents
@en
P2093
D C Talbot
D Mackintosh
G Deplanque
J P Braybrooke
T S Ganesan
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601218
P407
P577
2003-10-01T00:00:00Z